Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Cardiotoxicity 7Lymphoma, Non-Hodgkin 5Breast Neoplasms 5Neoplasms 4Lymphoma 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Lung Neoplasms 3Leukemia 3Hematologic Neoplasms 3Heart Failure 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Dyslipidemias 2Colonic Neoplasms 2Cardiovascular Diseases 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Ventricular Dysfunction, Left 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 28Paclitaxel 24Cisplatin 23Oxaliplatin 18Cytoreduction Surgical Procedures 17Carboplatin 17Fluorouracil 14Bevacizumab 10Mitomycin 9Leucovorin 9Doxorubicin 9Docetaxel 6Gemcitabine 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Neoadjuvant Therapy 4Laparoscopy 4Blood Specimen Collection 4Albumin-Bound Paclitaxel 4sodium thiosulfate 3liposomal doxorubicin 3catumaxomab 3Taxes 3Drug Therapy 3Chemotherapy, Adjuvant 3tremelimumab 2relacorilant 2pembrolizumab 2olaparib 2nintedanib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peritoneal Neoplasms × Electrocardiography × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡